Sema4 is a patient-centric health intelligence company that leverages advanced genomic testing and data analytics to support clinical decision-making and research initiatives. The company offers a broad portfolio of diagnostic tests spanning hereditary cancer risk assessment, prenatal carrier screening, pediatric disorders and pharmacogenetics. Through its proprietary data platform, Sema4 integrates genetic, clinical and socio-demographic information to deliver actionable insights that can inform prevention strategies, personalized treatment plans and population health management.
Founded in 2017 as a spin-out from Northwell Health, Sema4 is headquartered in Stamford, Connecticut, and serves healthcare providers, life sciences organizations and public health agencies across the United States. The company has established partnerships with leading health systems and academic institutions to advance large-scale research programs in areas such as oncology, rare disease and maternal-fetal health. Sema4’s laboratory operations are CLIA-certified and CAP-accredited, ensuring rigorous quality standards for its testing services.
Sema4’s technology platform combines cloud-based data infrastructure, machine learning algorithms and clinical decision support tools. In addition to its diagnostic offerings, the company collaborates with biopharmaceutical firms on drug development, biomarker discovery and real-world evidence studies. Under the leadership of CEO Eric Schadt, PhD, Sema4 continues to expand its capabilities in population genomics, digital health solutions and predictive modeling, with the goal of making precision medicine more accessible and scalable.
AI Generated. May Contain Errors.
